Sudo Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Sudo Biosciences's estimated annual revenue is currently $1.6M per year.
- Sudo Biosciences's estimated revenue per employee is $77,500
Employee Data
- Sudo Biosciences has 20 Employees.
- Sudo Biosciences grew their employee count by 54% last year.
Sudo Biosciences's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | Chief Development Officer | Reveal Email/Phone |
5 | Chief Business Officer | Reveal Email/Phone |
6 | Head Translational Pharmacology | Reveal Email/Phone |
7 | SVP, Medicinal Chemistry | Reveal Email/Phone |
8 | VP, CMC | Reveal Email/Phone |
9 | Senior Clinical Trial Manager | Reveal Email/Phone |
10 | Executive Assistant/Office Manager | Reveal Email/Phone |
Sudo Biosciences Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Sudo Biosciences?
Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel, best-in-class medicines to transform patients’ lives. Our lead programs target the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions.
keywords:N/AN/A
Total Funding
20
Number of Employees
$1.6M
Revenue (est)
54%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.5M | 20 | -39% | $38.5M |
#2 | N/A | 20 | 82% | N/A |
#3 | $2.1M | 21 | 0% | N/A |
#4 | $2.1M | 21 | -22% | N/A |
#5 | $2.1M | 21 | N/A | N/A |